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Abstract
Introduction: It has been demonstrated that the interplay of adhesion molecule CD44 and its ligands can regulate
cancer cell proliferation, migration and invasion, as well as tumor-associated angiogenesis and is related to breast
cancer patient survival. In this two-stage, case control study, we determined whether common functional tagSNPs
(single nucleotide polymorphisms) are associated with breast cancer risk and prognosis.
Methods: Five tagSNPs of CD44 (rs10836347C>T, rs13347C>T, rs1425802A>G, rs11821102G>A, rs713330T>C) were
selected and genotyped in 1,853 breast cancer patients and 1,992 healthy control subjects in Eastern and Southern
populations. Potential function of rs13347C>T and association between this variation and breast cancer were
further studied.
Results: Compared with the most common rs13347CC genotype, variant genotypes (CT and TT) increased an
individual’s susceptibility to breast cancer, especially in estrogen receptor (ER) negative patients (odds ratio (OR) =
1.37, 95%CI = 1.17 to 1.59 for ER positive patients; OR = 2.37, 95% CI = 2.00 to 2.80 for ER negative patients). We
also found that rs13347CT+ TT genotypes predicts lower five-year survival rate (hazard ratio (HR) = 1.85, 95% CI =
1.09 to 3.15, P = 0.023), with the lowest survival probability in ER negative T allele carriers. Furthermore, our
reporter assay findings, although preliminary and rather modest, showed that miR-509-3p may suppress CD44
expression more strongly in C allele carriers than T allele carriers (P < 0.01). Similarly, rs13347 variant genotypes
(CT and TT) carriers were shown to have more CD44 expression than CC carriers in both immunohistochemistry
(P < 0.001) and western blotting (P = 0.001) results.
Conclusion: These findings suggest that CD44 rs13347C>T polymorphism may affect breast cancer development
and prognosis by increasing CD44 expression.
Introduction
With gradually increasing incidence and mortality,
breast cancer refers to malignant tumor originating
from breast tissue, most commonly from the inner lin-
ing of milk ducts or the lobules that supply the ducts
with milk [1]. Excluding cervical cancer, it is the most
frequent cancer killer of middle-aged women [2]. Recent
studies have established some etiologic factor for breast
cancer, such as ionizing radiation [3], alcohol consump-
tion [4], high-fat diets [5], oral contraceptives and use of
hormones in treatment of certain diseases [6]. Excluding
these environmental factors, genetic variations also play
an important role in an individual’s risk of developing
breast cancer [7].
Compelling evidence has demonstrated that breast
cancers contain few phenotypically distinct cells, known
as breast cancer-initiating cells (BCICs), which account
for primary and metastatic tumor growth [8,9]. BCICs
can be distinguished from other breast cancer cells by
the expression of so-called CIC-markers that play a vital
role in BCIC maintenance and activity [10]. CD44 is one
of the well known markers of BCIC, which may contri-
bute not only to drug and radiation resistance of BCIC
but also preparation of the pre-metastatic niche [11].
By cell-cell and cell-extracellular matrix adhesive
interactions, CD44 participates in some fundamental
biological processes, including lymphocyte homing, cell
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migration, haematopoiesis, inflammation, wound heal-
ing, embryonal development and apoptosis [12]. Besides,
CD44 also plays an indispensable role in tumor pathol-
ogy, involved in cell differentiation, invasion and metas-
tasis [13-15]. Also, some studies reported strong
association between CD44 expression and breast cancer
aggressiveness [16,17]. Correspondingly, some studies
have recently indicated qualitative and quantitative
changes in CD44 expression in breast cancer [18].
Since expression of CD44 is closely related to develop-
ment of breast cancer and genetic variations in certain
genes may affect their expression [19], we hypothesize
that variations in CD44 that can theoretically affect its
protein expression may be associated with varying risk
and prognosis of breast cancer. In this study, five eligible
tag single nucleotide polymorphisms (tagSNPs) of CD44
gene were selected from the Genbank dbSNP database to
evaluate the contribution of detected polymorphisms to
risk of developing breast cancer. One of them is an A/G
polymorphism (rs1425802) in the promoter region, the
conversion from A to G cause loss of an Nkx-2 binding
site, which may theoretically affect the CD44 transcrip-
tional activity. Another T/C (rs713330) polymorphism in
the intron was linkage disequilibrium with the non-
synonymous rs9666607 G>A polymorphism, which may
change the 417 amino acid from Arg to Lys. The other
three polymorphisms (rs13347C/T, rs10836347C/T,
rs11821102G/A) all locate in the 3’UTR of CD44, each of
which can cause a change in the binding ability of certain
MicroRNA between the two different alleles. Only one
published research article has investigated polymorph-
isms in CD44 exon2 and breast cancer [20]; however, no
study has investigated the role of tagSNPs that cover all
common polymorphisms in breast cancer risk. So, we
carried out a hospital-based, case-control study including
1,853 breast cancer patients and 1,992 cancer free con-
trols to investigate the contribution of the five poly-
morphisms of CD44 to susceptibility to and prognosis of
breast cancer.
Materials and methods
Study subjects for case-control and follow-up study
All subjects in the case-control study were ethnically
homogenous Han Chinese derived from the Eastern
Chinese population or Southern Chinese population. In
the Eastern Chinese population, patients with newly
diagnosed breast cancer (n = 1,049) were consecutively
recruited from the First Affiliate Hospital of Soochow
University (Suzhou) during March 2001 to May 2009.
All the eligible patients diagnosed at the hospital during
the study period were recruited, with a response rate of
89%. Patients were recruited from Suzhou city and its
surrounding regions, and there were no age, stage and
histology restrictions. Population controls (n = 1,157)
were cancer-free people living in Suzhou region; they
were selected from a nutritional survey conducted in the
same period as the cases were collected [21]. In the
Southern Chinese population, breast cancer cases (n =
804) were recruited from the Tumor Hospitals affiliated
with Guangzhou Medical College between 2002 and
2009 with a response rate of 91%. Cancer-free controls
(n = 835) were randomly selected from a pool of 5,000
individuals who participated in a community-based
screening program for a health checkup conducted in
Guangdong province during the same time period when
the cases were recruited [22]. The pathological type and
tumor staging were evaluated according to the 2002
American Joint Committee on Cancer staging system.
The clinical features of the patients are summarized in
Additional file 1, Table S1. The patients were frequency
matched to controls on age. In Suzhou center, the aver-
age age was 49 years (range 21 to 79) for case patients,
and 49 years (range 20 to 81) for control subjects (P =
0.57); in Guangzhou center, the average age was 48
years (range 14 to 88) for case patients, and 47 years
(range 17 to 79) for control subjects (P = 0.60)
For the five-year survival rate study, 566 breast cancer
patients with relatively complete clinical information
from the First Affiliate Hospital of Soochow University
were followed up as the discovery set. Similarly, 331
patients from tumor hospitals affiliated with Guangzhou
Medical College were involved in the validation set.
Patients were followed-up by telephone calls every three
months and survival time was calculated from the date
when patients first received confirmed diagnoses until
the date of the last follow-up or death. Dates of death
were obtained from inpatient and outpatient records or
from the patients’ families through telephone follow-up.
Clinical features of the subjects for the follow-up studies
were shown in Additional file 2, Table S2.
At recruitment, informed consent was obtained from
each subject. This study was approved by the Medical
Ethics Committee of The First Affiliate Hospital of Soo-
chow University and Tumor Hospitals affiliated with
Guangzhou Medical College.
TagSNPs selection
Bioinformatics analysis with Haploview software 4.2
(Mark Daly’s lab of Broad Institute, Cambridge, MA,
Britain) was performed to analyze the haplotype block
based on the CHB (Chinese Han Beijing) population
data of HapMap (HapMap Data Rel 27 PhaseII +III, Feb
09, on NCBI B36 assembly, dbSNP b126 (International
HapMap Project). Six tagSNPs were found to cover all
the potential functional common SNPs (MAF > 0.05) in
the CD44 gene: rs8193, rs11821102, rs10836347 and
rs13347 in the 3’UTR, rs1425802 in the promoter and
rs9666607 in exon region (Additional file 3, Figure S1).
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Among them, rs8193 and rs13347 were in high linkage
disequilibrium (LD) (D’ = 1.0, r2 = 0.527), so the selec-
tion of rs13347 is enough to represent the two SNPs.
Besides, due to the difficulty in genotyping rs9666607 by
MALDI-TOF method, we chose rs713330, which is in
complete LD with rs9666607 (D’ = 1.0, r2 = 1) to
replace it.
Genotyping analysis
Genomic DNA was isolated from the peripheral blood
lymphocytes of the study subjects. MassArray (Seque-
nom, San Diego, CA, USA) was used for genotyping all
markers using allele-specific MALDI-TOF mass spectro-
metry [23]. Primers and multiplex reactions were
designed using the RealSNP.com Website. All breast
cancer patients and healthy controls in Suzhou center
were genotyped for rs10836347, rs13347, rs1425802,
rs11821102 and rs713330 polymorphisms. Patients and
controls from Guangzhou center were genotyped only
for the polymorphism rs13347 to warrant the results of
Suzhou.
Construction of CD44 3’UTR luciferase reporter plasmids
Based on bioinformatics analysis, CD44 rs13347 C not T
is predicted to lie in a hsa-mir-509-3p binding site.
Therefore, we hypothesized that hsa-mir-509-3p would
bind tightly to CD44 mRNA transcripts containing the
C allele, negatively regulating CD44 expression. To test
this hypothesis, the T and C allelic reporter constructs
were respectively prepared by amplifying a 362-bp CD44
3’UTR region from subjects homozygous for the T and
C allele, including the artificial XhoI and NotI enzyme
restriction sites with forward primer 5’-ATCG
CTCGAG GGCCATTGTCAACGGAGA-3’ and reverse
primer 5’- ATGC GCGGCCGC CAGGCTTGAAA-
TATGGATTCG-3’. The amplified fragments were then
cleaved with the XhoI and NotI enzymes (New England
BioLabs, Ipswich, MA, USA). The psiCHECK2 vector
(Promega, Madison, WI, USA) was also cleaved with the
XhoI and NotI enzymes, and the above-prepared frag-
ment and psiCHECK2 vector were then ligated by T4
DNA ligase (New England BioLabs). The two constructs
were sequenced to confirm the allele, the orientation
and integrity of each insert.
Transient transfections and luciferase assays
293T or MCF-7 cells were maintained in Dulbecco’s
modified Eagle’s medium with high glucose (Gibco, Los
Angeles, California, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco) and 50 μg/ml
streptomycin (Gibco) at a 37°C incubator supplemented
with 5% CO2. Cells were seeded at 1 × 105 cells per
well in 24-well plates (BD Biosciences, Bedford, MA,
USA). Sixteen hours after the plating, cells were
transfected by Lipofectamin 2000 (Invitrogen, Carlsbad,
California, USA) according to the manufacturer’s sug-
gestion. In each well, 800 ng psiCHECK-2-CD44-3’UTR
vectors were co-transfected with 50 pmol hsa-mir-509-
3p mimics (Ambion, Austin, TX, USA) and 40 pmol
hsa-mir-509-3p inhibitor accordingly. The hsa-mir-509-
3p inhibitor is single-stranded RNA molecules, which
can specifically knock-down endogenous hsa-mir-509-
3p. In addition, 100 pmol Negative Control #1 from
Ambion was in every transfection experiment. There are
six replicates for each group and the experiment is
repeated at least three times. Twenty-four hours after
transfection, cells were harvested by passive adding of
100 μl buffer. Renilla luciferase activities in cell lysate
were measured with the Dual-Luciferase Reporter assay
system (Promega) in TD-20/20 luminometer (Turner
Biosystems, Sunnyvale, CA, USA) and were normalized
with the firefly luciferase activities.
Western blotting analysis
To analyze the correlation between rs13347 C>T poly-
morphism in 3’ UTR of CD44 and the protein expres-
sion levels in breast cancer tissues, Western blotting
assays were performed. Generally, 39 breast cancer tis-
sues were homogenized in 800 μl detergent lysis buffer
and then the tissue homogenates were centrifuged at
12,000 g for 15 minutes to get the supernatant. Sixty
micrograms of total proteins (the supernatant) were run
on a SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF (Millipore, Billerica,
MA, USA). The membrane was blocked with 5% milk in
tris-buffered saline (TBS) with 0.05% Tween-20 for one
hour at room temperature with constant agitation. The
polyclonal antibody against CD44 and the monoclonal
antibody against GAPDH were both purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The
membranes were incubated overnight at 4°C with the
primary antibody diluted 1:1,000 and the proteins were
detected with a Phototope-horseradish peroxidase
Western blot detection kit (Cell Signaling Technology,
Danvers, MA, USA). The CD44 protein expression levels
were normalized to that of GAPDH by calculating the
relative expression levels.
Immunohistochemistry analysis
After screening hematoxylin and eosin-stained slides for
optimal tumor content, we constructed tissue slides.
Cores were taken from each formalin-fixed, paraffin-
embedded breast cancer samples by using punch cores
that measured 0.8 mm in greatest dimension from the
center of tumor foci. Immunohistochemistry for CD44
was performed by using the avidin-biotin complex
method (ABC; Vector Laboratories, Burlingame, CA,
USA), including heat-induced antigen-retrieval
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procedures. Primary antibodies were mouse antihuman
monoclonal antibodies combined with CD44 (1:200;
Santa Cruz Biotechnology,). The components of the
Envision-plus detection system (EnVision+/HRP/Mo;
Dako, Carpinteria, CA, USA) were applied. Reaction
products were visualized by incubation with 3, 3’-diami-
nobenzidine. Negative controls were treated identically
but with the primary antibody omitted. The images of
stained slides were obtained and evaluated by experi-
enced pathologists. The percentage of positive tumor
cells was determined and graded (0 to 5): 0% (0), 1 to
20% (1), 21 to 40% (2), 41 to 60% (3), 61 to 80% (4) and
> 81% (5) [24].
Statistical analysis
Two-sided chi-square tests were used to assess differ-
ences in the distributions of age, menstrual history,
body mass index (BMI) and family history of breast can-
cer between cases and controls as well as the allele and
genotypes. The Hardy-Weinberg equilibrium (HWE)
was tested by a goodness-of-fit chi-square test to com-
pare the expected genotype frequencies with observed
genotype frequencies (p2 + 2pq + q2 = 1) in cancer-free
controls. The association between case-control status
and each SNP, measured by the odds ratio (OR) and its
corresponding 95% confidence interval (CI), was esti-
mated using an unconditional logistic regression model,
with and without adjustment for age, BMI and family
history of cancer. Logistic regression modeling was also
used for the trend test [25,26]. The data were further
stratified by age, age at menarche (years), menstrual his-
tory, BMI, pathological type, stage, estrogen receptor
status, progesterone receptor status and family history
of cancer to evaluate the stratum variable-related ORs
among the CD44 genotypes. Homogeneity among stra-
tum variable related ORs was tested [25]. The associa-
tions between overall survival time and demographic
and clinical characteristics were estimated using the
Kaplan-Meier method and Log-rank test by SAS. The
effect modifications by these characteristics and the
effects of SNPs on death risk in patients with breast
cancer were assessed using the Wald test in the multi-
variate Cox proportional hazards regression models after
adjusting for the confounders. The proportional hazards
assumption was examined by testing interactions
between the genotypes and time (all P-value > 0.05).
The differences in the luciferase reporter activity, nor-
malized expression values and protein level in cancer
tissue of CD44 (Western blot ratio and IHC scores)
between each allele were analyzed by Kruskal-Wallis
one way ANOVA. The tests were all two-sided and ana-
lyzed using the SAS software (version 9.1; SAS Institute,
Cary, NC, USA). P < 0.05 was considered statistically
significant.
Results
Genotypes and risk of breast cancer
The association of breast cancer with rs13347C>T was
performed by two independent laboratories at Soochow
University and Guangzhou Medical College in Eastern
(1,049 cases and 1,157 controls, Jiangsu Province) and
Southern (804 cases and 835 controls, Guangdong Pro-
vince) Chinese populations. The polymorphisms
rs10836347, rs1425802, rs11821102 and rs713330 were
only genotyped in the Suzhou population (1,049 cases and
1,157 controls) (Additional file 4, Figure S2). Genotypes
were confirmed by direct sequencing (Additional file 5,
Figure S3). The observed genotype frequencies of the four
polymorphisms in controls conformed to the HWE (P =
0.84 for rs13347, 0.97 for rs10836347, 0.55 for rs1425802,
0.22 for rs11821102, P = 0.39 for rs713330 in the Eastern
population; and P = 0.89 for rs13347 in the Southern
population, respectively). Genotyping results showed that
only rs13347 was statistically, significantly associated with
breast cancer in both Eastern and Southern Chinese popu-
lations (Table 1). In the Eastern Chinese population, the
frequency of the rs13347 TT and CT genotype was signifi-
cantly higher in patients with breast cancer (Ptrend < 10
-5)
compared to the healthy controls. The adjusted OR of car-
rying the rs13347 CT and TT genotype in Suzhou cancer
patient groups were 1.69 and 2.22, respectively, compared
with the rs13347 CC genotype. The association was con-
firmed in the Southern population where the odds of car-
rying the rs13347 CT and TT genotype in cancer patient
groups were 1.61 (95% CI = 1.31 to 1.98) and 2.25 (95% CI
= 1.51 to 3.35), respectively, compared with the rs13347
CC genotype (Ptrend < 10
-5).
Stratification analysis of CD44 rs13347 genotypes and risk
of breast cancer
The risk of breast cancer related to CD44 rs13347 geno-
types were further examined with stratification by age,
age at menarche, menstrual history, BMI and family his-
tory of breast cancer, pathological type, clinical stage,
estrogen receptor status and progesterone receptor sta-
tus. As shown in Figure 1, we observed significant dif-
ference in the genotype frequency between ER-negative
patients and ER-positive patients (P < 10-5). Compared
with the CC genotype, the T allele carriers (CT+TT)
had 2.37-fold increased risk of developing breast cancer
in ER-negative patients. As for the ER-positive patients,
the increased risk of CT+TT is only 1.37-fold. However,
there were no differences in other subgroups.
Regulation effects of hsa-mir-509-3p on CD44 3’UTR
translation efficiency
Compared with the psiCHECK-2-CD44-3’UTR-rs13347
T, the translation of Renilla luciferase of psiCHECK-2-
CD44-3’UTR-rs13347 C was significantly reduced in the
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ORa (95% CI) P-valueb
Discovery Set N = 1,157 N = 1,049
rs13347 C>T
CC 654 (56.5) 451 (43.0) 1.00 (reference)
CT 430 (37.2) 484 (46.1) 1.69 (1.40 to 2.04) < 10-5
TT 73 (6.3) 114 (10.9) 2.22 (1.59 to 3.10)
CT+TT 503 (43.5) 598 (57.0) 1.77 (1.48 to 2.12)
C 1,738 (75.1) 1,386 (66.1) 1.00 (reference)
T 576 (24.9) 712 (33.9) 1.57 (1.37 to 1.80)
rs10836347 C>T
CC 995 (86) 906 (86.4) 1.00 (reference)
CT 156 (13.5) 139 (13.2) 0.98 (0.76 to 1.27)
TT 6 (0.5) 4 (0.4) 0.66 (0.18 to 2.43) 0.743
CT+TT 162 (14) 143 (13.6) 0.97 (0.75 to 1.25)
C 2,146 (92.7) 1,951 (93.0) 1.00 (reference)
T 168 (7.3) 147 (7.0) 0.96 (0.75 to 1.22)
rs1425802 A>G
AA 353 (30.5) 316 (30.1) 1.00 (reference)
AG 563 (48.7) 513 (48.9) 1.04 (0.85 to 1.27)
GG 241 (20.8) 220 (21.0) 1.06 (0.82 to 1.36) 0.861
AG+GG 804 (69.5) 733 (69.9) 1.04 (0.86 to 1.27)
A 1,269 (54.8) 1,145 (54.6) 1.00 (reference)
G 1,045 (45.2) 953 (45.4) 1.03 (0.91 to 1.17)
rs11821102 G>A
GG 997 (86.2) 912 (86.9) 1.00 (reference)
AG 151 (13) 125 (12.0) 0.85 (0.65 to 1.12)
AA 9 (0.8) 12 (1.1) 1.76 (0.70 to 4.470 0.802
AG+AA 160 (13.8) 137 (13.1) 0.90 (0.69 to 1.16)
A 169 (7.3) 149 (7.1) 1.00 (reference)
G 2,145 (92.7) 1,949 (92.9) 0.95 (0.74 to 1.21)
rs713330 T>C
TT 950 (82.1) 865 (82.5) 1.00 (reference)
CT 194 (16.8) 172 (16.4) 0.97 (0.77 to 1.23)
CC 13 (1.1) 12 (1.1) 1.01 (0.43 to 2.38) 0.853
CT+CC 207 (17.9) 184 (17.5) 0.98 (0.78 to 1.22)
T 2,094 (90.5) 1,902 (90.7) 1.00 (reference)
C 220 (9.5) 196 (9.3) 0.98 (0.80 to 1.21)
Validation Set N = 835 N = 804
rs13347 C>T
CC 492 (58.9) 362 (45.0) 1.00 (reference)
CT 297 (35.6) 366 (45.5) 1.61 (1.31 to 1.98)
TT 46 (5.5) 76 (9.5) 2.25 (1.51 to 3.35) < 10-5
CT+TT 343 (41.1) 442 (55.0) 1.69 (1.39 to 2.07)
Pooled Analysis N = 1,992 N = 1,853
rs13347 C>T
CC 1,146 (57.5) 813 (43.9) 1.00 (reference)
CT 727 (36.5) 850 (45.9) 1.64 (1.43 to 1.89)
TT 119 (6.0) 190 (10.2) 2.17 (1.68 to 2.80) < 10-5
CT+TT 1,886 (42.5) 1,040 (56.1) 1.72 (1.51 to 1.96)
aData were calculated by unconditional logistic regression, adjusted for age, BMI and family history of breast cancer. bTests for trend of odds were two-sided and
were based on likelihood ratio tests assuming a multiplicative model.
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presence of hsa-mir-509-3p in a concentration-depen-
dent manner (P < 0.001), which distinguished the magni-
tude of the effects of hsa-mir-509-3p on the transcription
of different alleles in 293T cells (Figure 2A). The same
experiments were repeated in MCF-7 cells and similar
results were obtained (Figure 2B). When psiCHECK-2-
CD44-3’UTR with 50 pmol hsa-mir-509-3p and its corre-
sponding inhibitor were cotransfected into 293T and
MCF-7 cells separately, there appeared no significant dif-
ference in luciferase activity between the two recombi-
nants (Figure 2C). These results suggest that, indeed,
hsa-mir-509-3p can binds and negatively regulate the
transcription of CD44 in the presence of rs13347 C allele.
Effects of CD44 rs13347C>T variation on CD44 protein
levels
As shown in Figure 3 and Additional file 6, Table S3, we
collected 39 tumor tissues from the untreated breast
cancer patients with different genotypes and found that
the levels of CD44 protein of seven cases carrying the
TT genotype (0.838 ± 0.127) and 17 cases carrying the
TC genotype (0.465 ± 0.243) were significantly higher
than that of other 15 cases carrying the CC genotype
(0.238 ± 0.067) (ANOVA test: P < 0.001).
To confirm the results of Western blotting, we further
performed the IHC study in 31 breast cancer tissues to
verify association between expression level of CD44 pro-
tein and rs13347C >T in vivo (Figure 3C and Additional
file 7, Table S4). CD44 protein expression levels in breast
cancer tissues of 15 patients carrying the CC genotype
were significantly lower than that in 12 patients carrying
the CT or 4 patients carrying TT genotype (Kruskal Wallis
Test: P = 0.003).
CD44 rs13347C>T variation and five-year survival of
breast cancer patients
The demographic and clinical characteristics of breast
cancer patients in the survival discovery and validation
sets are summarized in Additional file 2, Table S2. In
the discovery set, the mean age was 48 years, among
them, 63 (11.1%) patients died of breast cancer, 269
(47.5%) were ER negative, 242 (42.8%) were PR negative.
In the validation set with the same mean age 48, 62
(18.7%) patients died of breast cancer, 139 (42.0%) were
ER negative, 133 (40.2%) were PR negative. The five-
year survival rates in the two sets were 88.9% and
81.3%, respectively. The Kaplan-Meier analysis, Log-rank
test and univariate Cox analysis revealed that breast can-
cer patients that are ER or PR positive have a signifi-
cantly decreased death risk (P = 0.0017 and P = 0.002,
respectively). There were no significant effects of other
characteristics.
Multivariate proportional hazards regression models
and the Log-rank test revealed that, when compared
with the rs13347 CC genotype, the rs13347 CT+TT
genotypes were associated with poor survival (adjusted
HR = 1.849 and P = 0.0233) and a lower survival prob-
ability (Log-rank P = 0.0211) (Table 2).
The rs13347C > T polymorphism was further tested in
the validation set. In this dataset, when compared with
the rs13347CC genotype, the CT and TT genotypes
were associated with poor survival (adjusted HR =
2.104, 3.144 and P = 0.0081, 0.015, respectively) and
rs13347 CT+TT genotypes had a 2.34-fold increased
death risk (P = 0.0010). Also, in the pooled analysis of
the two cohorts we found that the rs13347 CT or
rs13347 TT genotype had a 1.54-fold or 2.84-fold
increased death risk (P = 0.00378 and P < 0.001) and
the HR is 1.873 (P = 0.0007) for the CT+TT carriers
(Table 2). As is also shown in Figure 4A, B, CT or TT
carriers have lower survival probability in discovery set,
validation set and pooled analysis. The contribution of
interaction between rs13347 variation and ER status to a
five-year survival rate of breast cancer patients was
further investigated and it was found that ER negative T
carriers yield the lowest survival probability (Figure 4C).
Figure 1 Stratification analysis of CD44 rs13347C>T polymorphism on breast cancer risk. ORs were adjusted for age in a logistic
regression model. P-value of the test for multiplicative interaction between stratum-related variables and CD44 rs13347C>T genotypes (n, the
number of CT and TT genotypes; N, the number of CC, CT and TT genotypes).
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However, no significant contribution was found in the
other four polymorphisms.
Discussion
Associations between breast cancer susceptibility and
CD44 polymorphisms have not been detected in any
population using case-control studies. In this molecular
epidemiological study we sought to identify genetic
factors that confer individual susceptibility to breast
cancer. Our results obtained by analyzing 1,853 breast
cancer patients and 1,992 controls from two study cen-
ters showed that the functional variation rs13347 T in
the CD44 was associated with increased risk for devel-
oping breast cancer and yields lower five-year survival
probability. However, there exists no significant differ-
ence in the susceptibility and prognosis affect to breast
Figure 2 Reporter gene expression assays modulated by hsa-mir-509-3p with constructs containing 362-bp of CD44 3’UTR.
Representative graph of luciferase activity of variant allele on luciferase reporter genes bearing 3’ UTR segments from Human CD44 in 293T (A)
and MCF-7 cells (B). Results are shown as percentage relative to luciferase activity (Renilla luciferase activity was measured and normalized to
Firefly luciferase). (C) Relative luciferase activity of the psiCHECK-2-CD44-3’UTR-C-allele and psiCHECK-2-CD44-T-allele constructs co-transfected
with 40 pmol hsa-mir-509-3p and inhibitor. Assay was performed in 293T and MCF-7 cells. Six replicates for each group and the experiment
repeated at least three times. Data are mean ± SE. *P < 0.01 compared with C allele.
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cancer between different genotypes of the other four
polymorphisms.
CD44 is a ubiquitously expressed family of cell adhesion
glycoproteins comprising an N-terminal extracellular
domain, a membrane proximal region, a transmembrane
domain and a cytoplasmic tail. The family is coded by the
human CD44 gene, which is mapped to chromosomal
locus 11p13 and is composed of two groups of exons [27].
Exons 1 to 5 and 16 to 20 are spliced together to form a
transcript encoding the ubiquitously expressed standard
isoform (CD44s). The variable exons 6 to 5 (known as v1
to 10) can be alternatively spliced and inserted to the stan-
dard form between exons 5 and 16 [28]. The multiple
functions of the CD44 family are generated by their bind-
ing of HA (hyaluronic acid) and some other extracellular
molecules [28]. CD44 regulates breast cancer through sev-
eral mechanisms. Interaction of hyaluronan and CD44 can
promote breast cancer cell adhesion and inhibited invasion
[29]. Besides, binding of hyaluronan to CD44v3 can stimu-
late breast cancer cell growth, survival and invasion
through the Rho and PI3K-AKT signaling pathways [30].
Moreover, the migration of metastatic breast cancer cells
can be increased by the interaction of CD44v3, 8 to 10
with ankyrin promoted by Rho kinase [31]. Based on the
above, it is reasonable to predict that changes in the
expression or function of CD44 will play a pivotal role in
the development and progression of breast cancer. Krech
R. et al. reported a significant increase in the CD44
expression in breast cancer compared to normal breast
epithelium [18]. These findings correspond with our
results that CD44 rs13347 T carriers possess higher pro-
tein levels and, therefore, they are more susceptible to
breast cancer and have poorer prognosis.
Much interest has been generated by the recent discov-
ery that CD44 is a surface marker of BCICs [9]. Lin et al.
found that CD44posCD24neg and CD44posCD24poscell
populations in estrogen receptor (ER) a-negative breast
tumors are tumorigenic in murine xenograft models,
which indicate CD44 as a hallmark of BCIC in ER-nega-
tive breast cancer [32]. Similarly, in a study examining
the expression profile of cancer stem cell markers in
eight human breast cancer cell lines, Lee et al. found that
CD44 was expressed mostly in basal-like cell lines,
including MDA-MB-468, MDA-MB-231 and HCC1937,
which were all ER negative [33]. Recently, substantial
progress has been made in the identification of BCICs
and there is accumulating evidence that these cells might
be targets for transformation during mammary carcino-
genesis [9]. Since CD44 contributes much to BCICs’
maintenance and activity as its surface marker and
BCICs play an important role in breast cancer tumori-
genesis, it is inferable that the possible quantitative
change of CD44 caused by rs13347 C/T mutation will
affect breast cancer development, especially in ER-nega-
tive patients. In addition, the expression of ER also has
important prognostic implications; that is, ER-positive
Figure 3 Association between the CD44 rs13347C>T polymorphism and the CD44 protein expression. (A) CD44 protein levels in 39
breast cancer tissues from individuals who carried different rs13347 genotypes. The CD44 protein expression levels were normalized to that of
GAPDH by calculating the relative expression levels. (B) Analysis of protein levels in 39 breast cancer tissues from individuals who carried
different genotypes. (C) Immunohistochemistry analysis of CD44 protein expression levels in breast cancer tissues. HE staining (above) and CD44
antibody staining (below) (SP, ×40, ×100, ×200).
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tumors have a better prognosis in terms of overall survi-
val, while ER-negative tumors have a more aggressive
phenotype and poorer survival probability [34-36].
Although the exact mechanism is still unclear, there will
be no doubt that some risk factor will do more for breast
cancer generation, development and prognosis in ER-
negative patients. These previous study results and infer-
ences are consistent with our findings that the parlous
role of rs13347 CT+TT is more pronounced in ER-nega-
tive patients and ER negative rs13347 T allele-carrying
patients yield the minimum survival probability.
Although we have found that CD44 rs13347 variant
genotypes (CT+TT) were associated with increased risk
for breast cancer, our study may have certain limitations
caused by the study design. For example, selection bias
and/or systematic error may occur because the cases
were from the hospital and the controls were from the
community. Selection bias is a particular problem inher-
ent in case-control studies, where it gives rise to non-
comparability between cases and controls. In case-con-
trol studies, controls should be drawn from the same
population as the cases, so they are representative of the
population which produced the cases. In our present
study, cases and controls in each center were collected
from the same place during the same time and the
breast cancer patient samples in our study were sporadic
cancer patients, reducing the probability of selection
bias from the maximum extent. Moreover, the fact that
we have achieved a more than 95% study power (two-
sided test, a = 0.05) to detect an OR of 1.72 for the
Table 2 Associations between CD44 genotypes and five-year survival of breast cancer
SNPs Hazard ratio
(95% CI)
P* Breast cancer patients Death Log-rank
P
Discovery Set N = 566 N = 63
rs10836347 C>T
CC 1.00 (Reference) 481 (85.0) 55
CT+TT 0.89 (0.42 to 1.88) 0.753 85 (15.0) 8 0.5854
rs1425802 A>G
AA 1.00 (Reference) 164 (29.0) 24
AG 0.63 (0.37 to 1.09) 0.102 276 (48.8) 28 0.2274
GG 0.73 (0.51 to 1.05) 0.091 126 (22.2) 11
AG+GG 0.61 (0.36 to 1.01) 0.056 402 (71.0) 39 0.0951
rs11821102 G>A
GG 1.00 (Reference) 484 (85.5) 54
AG+AA 0.93 (0.45 to 1.91) 0.845 82 (14.5) 9 0.973
rs713330 T>C
TT 1.00 (Reference) 468 (82.7) 51
CT+CC 1.14 (0.59 to 2.20) 0.676 98 (17.3) 12 0.6883
rs13347 C>T
CC 1.00 (Reference) 255 (45.1) 20
CT 1.36 (0.75 to 2.47) 0.3189 223 (39.4) 23 0.0004
TT 3.18 (1.71 to 5.91) 0.0003 88 (15.5) 20
CT+TT 1.85 (1.09 to 3.15) 0.0233 311 (54.9) 43 0.0211
Validation Set N = 331 N = 62
rs13347 C>T
CC 1.00 (Reference) 200 (60.4) 26
CT 2.10 (1.21 to 3.65) 0.0081 100 (30.2) 25 0.0012
TT 3.14 (1.55 to 6.38) 0.0015 31 (9.4) 11
CT+TT 2.34 (1.41 to 3.88) 0.0010 131 (39.6) 36 0.0007
Pooled Analysis N = 897 N = 125
rs13347 C>T
CC 1.00 (Reference) 455 (50.7) 46
CT 1.54 (1.02 to 2.30) 0.0378 323 (36.0) 48 < 0.0001
TT 2.84 (1.80 to 4.48) < 0.0001 119 (13.3) 31
CT+TT 1.87 (1.30 to 2.70) 0.0007 442 (49.3) 79 0.0006
*The Cox regression analysis was adjusted for age, BMI, family history, TNM stage, estrogen receptor status, progesterone receptor status, pathological type,
menopausal status and age at menarche.
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rs13347 CT+TT genotypes, which occurred at a fre-
quency of 42.5% in the controls, compared with the
rs13347 CC genotype, suggesting that this finding is
noteworthy.
Conclusions
Our study indicated that compared with the CD44
rs13347 CC genotype, the variant genotypes (CT+TT) can
elevate the risk of breast cancer and predicts poorer five-
year survival rate in both Southern and Eastern Chinese
populations. Moreover, the phenomenon is more obvious
in ER-negative breast cancer patients. To our best knowl-
edge, our study first demonstrated a significant association
between the CD44 rs13347 C/T polymorphism and risk of
breast cancer. Moreover, larger, preferably population-
based case-control studies, as well as well-designed
mechanistic studies, are warranted to validate our findings
in Chinese populations or to investigate the association
between this polymorphism with different tumors in dif-
ferent ethnicities.
Additional material
Additional file 1: Distributions of characteristics among breast
cancer patients and controls in Chinese populations used for
association study. Age, age at menarche, body mass index, family
history, pathological type, stage, estrogen receptor status and
Figure 4 Kaplan-Meier curves about survival probability in different rs13347C>T genotype carriers. (A) difference in survival probability
between CC, CT and TT carriers (B) difference in survival probability between CC and CT+TT carriers (C) difference in survival probability
between ER+CC, ER+CT+TT, ER-CC and ER-CT+TT carriers.
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progesterone receptor status distributions among breast cancer patients
and healthy controls from Suzhou and Guangzhou center.
Additional file 2: Demographic and clinical characteristics of breast
cancer patients in the five-year survival discovery and validation
sets. Age, age at menarche, body mass index, family history, pathological
type, stage, estrogen receptor status and progesterone receptor status
distributions among the patients and healthy controls used for five-year
survival analysis from Suzhou and Guangzhou center.
Additional file 3: Haplotype block analysis of polymorphisms in
CD44 gene. Six potential functional SNPs (minor allele frequency > 5%)
were used to analyze the haplotype block based on the CHB (Chinese
Han Beijing) population data of HapMap.
Additional file 4: Genotyping analysis of candidate SNPs. The figure
shows representative MALDI-TOF mass spectrometry profiles for different
allelic PCR products containing the CD44 rs13347, rs10836347, rs1425802,
rs11821102 and rs713330 polymorphism sites.
Additional file 5: Direct sequencing of candidate SNPs. CD44 rs13347,
rs10836347, rs1425802, rs11821102 and rs713330 genotyping by direct
sequencing.
Additional file 6: Western blotting analysis in different rs13347
genotypes carriers. Relative CD44 expression in 15 CC samples, 17 CT
samples and 7 TT samples.
Additional file 7: Immunohistochemistry assay in different rs13347
genotypes carriers. CD44 immunohistochemistry assay results in 15 CC
samples, 12 CT samples and 4 TT samples.
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